)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Syndax Pharmaceuticals (SNDX) investor relations material
Syndax Pharmaceuticals Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary11 Nov, 2025
Business overview and recent performance
Two newly commercialized oncology products launched, both showing strong initial uptake and revenue growth.
Revumenib achieved $32 million in quarterly sales with 25% script growth, and is the first approved drug for KMT2A, targeting a 2,000-patient market.
Niktimvo, a CSF1R antibody for third-line cGVHD, reached $46 million in net sales in its second quarter and became profitable.
Company aims for 50% market penetration in KMT2A by year-end and plans to expand into NPM1 as the next growth driver.
Cash position of $456 million supports plans for cash flow break-even and further product expansion.
Growth drivers and market dynamics
Revumenib is increasingly used earlier in treatment, with 70% of patients receiving it in second or third line, driving growth.
Maintenance therapy post-transplant is emerging as a significant revenue lever, with 35%-40% of patients returning, expected to rise to 70%-80%.
Combination therapy with venetoclax and azacitidine is gaining traction, with 30%-40% of use now in combinations.
NPM1 expansion expected to mirror KMT2A adoption, with strong physician interest in combination regimens.
Competitive positioning is strong due to broad indications, best-in-category efficacy, and flexible dosing.
Clinical development and future outlook
Ongoing studies in maintenance and combination settings, with new data expected at ASH and from the Evolve 2 HOVON phase 3 study.
Evolve 2 study leverages academic partnerships for speed and quality, aiming for first readout in frontline AML.
Niktimvo is being developed for frontline GVHD and in combination with steroids and Jakafi, targeting a $1-2 billion market opportunity.
Co-development with Incyte yields a 50/50 profit split, with 25%-30% of top-line revenue contributing to the company.
Niktimvo is also in phase 2 for idiopathic pulmonary fibrosis, with data expected mid-next year and potential for broader fibrosis indications.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Syndax Pharmaceuticals earnings date
Stifel 2025 Healthcare Conference13 Nov, 2025
Next Syndax Pharmaceuticals earnings date
Stifel 2025 Healthcare Conference13 Nov, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for cancer. The company's lead programs target immune pathways and tumor microenvironments to enhance the body’s ability to fight cancer. Syndax's pipeline includes treatments for both solid tumors and hematologic cancers, aiming to address unmet medical needs by improving outcomes for cancer patients through novel combination therapies. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage